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Purpose: Alteration of CyclinD1 was suggested to relate with development of endometrial carcinogenesis before,
however CyclinD1 expression is not well defined in endometrial hyperplasia lesions. We checked the relationship
between its expression and clinic-pathological variables of endometrial lesions to explore the possibility for
CyclinD1 as a potential diagnostic and prognostic marker.
Methods: Cyclin D1 immunohistochemical analysis (IHC) was used to evaluate 201 fixed, paraffin-embedded
endometrial samples which included simple hyperplasia (n = 27), atypical complex hyperplasia (ACH) (n = 41),
endometrioid carcinoma (n = 103), endometrial serous carcinoma (ESC) (n = 21) and clear cell carcinoma (CCC)
(n = 9). A breast cancer with known CyclinD1 expression was selected as a positive control in each
immunohistochemistry run. We also performed follow-up study to estimate patients’ prognosis.
Results: CyclinD1 was significantly overexpressed in atypical complex hyperplasia (ACH), endometrioid carcinoma
and clear cell carcinoma (CCC). The positive signaling of CyclinD1 was showed less than 40% in simple hyperplasia
and endometrial serous carcinoma (ESC). The high expression of CyclinD1 was observed in metastasis carcinoma
group more significantly than non-metastasis carcinoma group. Kaplan Meier analysis demonstrated that patients
with high CyclinD1 expression had an obviously poor prognosis than patients without CyclinD1 staining (p < 0.05).
Moreover, according to multivariate Cox regression analysis, CyclinD1 expression, as crucial as metastasis, was a risk
marker for overall survival rate.
Conclusion: CyclinD1 exhibited a promising potential to predict the prognosis of patients with endometrial
carcinoma. However, the statistical analysis demonstrated that CyclinD1 exhibited a poor ability to differentiate
neoplastic lesions from non-neoplastic lesions; thus, the application of CyclinD1 only is not so credible for
differentiation between benign and malignant lesions.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1871063048950173.
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Endometrial cancer is the most common malignancy of
the female genital tract in the world and the seventh
most common cause of death for women in Western
Europe who suffer from cancer. Every year 7406 new
cases are registered in the UK, 88 068 in the European
Union and 40 102 in North America [1]. Even though
the routine evaluation of estrogen receptor (ER),* Correspondence: ztguo@sdu.edu.cn
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reproduction in any medium, provided the orprogesterone receptor (PR) and P53 expression in endo-
metrial cancers are widely used, corpus uteri cancer,
lacking new effective prognostic markers, still severely
jeopardizes women’s health today. In that case, we are
looking forward to some new diagnostic and predict in-
dicators more accurately and credibly.
CyclinD1 (also known as BCL1) which is best known
for its utility in mantle cell lymphoma diagnosis is
encoded by the CCND1 gene in human beings [2-4].
As a cell -cycle regulator, CyclinD1 is essential for
progression through G1 phase and is a candidate
proto-oncogene [5]. Mutations, amplification and over-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The expression of CyclinD1 tested by immunohistochemistry. (original magnifications: 400×). A: CyclinD1 immunostaining in
simple hyperplasia endometrial tissue, cells with a brown-stained nucleus are regarded as positive. However, negative CyclinD1 immunostaining
was seen in the picture. (original magnifications: 400×); B:CyclinD1 staining in atypical complex hyperplasia. CyclinD1 is weakly to moderately
positive in most grandular epithelium cells (original magnifications: 400×); C: CyclinD1 staining in endometrioid carcinoma. CyclinD1 was strongly
and diffusely positive in nucleus (original magnifications: 400×). D: CyclinD1 staining patterns in endometrial serous carcinoma, CyclinD1
expression in ESC mostly showed a strong intensity in nucleus. (original magnifications: 400×). E:SET8 expression in endometrial clear cell
carcinoma. The picture showed a moderate intensity of SET8 staining. (original magnifications: 400×).
Liang et al. Diagnostic Pathology 2013, 8:138 Page 2 of 8
http://www.diagnosticpathology.org/content/8/1/138





+ - Positive Rate%*
Simple hyperplasia 27 8 19 30%
Atypical complex hyperplasia 41 20 21 49%
Endometrioid carcinoma 103 54 49 52%
Endometrial serous carcinoma 21 8 13 38%
Clear cell carcinoma 9 6 3 67%
*: Grade and score by the intensity of immunoreactivity staining: 0 point for
absent, 1 point for weak, 2 points for moderate and 3 points for strong; then
grade by the extent of tissue staining: 0 point for no positive staining cells, 1
point for positive ratio <25%, 2 points for 25%-49%, 3 points for 50%-79% and
4 points for ≥ 80%. Finally, multiply the two score systems: ≤3 points for
negative, >3 points for positive.
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progression, are observed frequently in a variety of tu-
mors and may contribute to tumorigenesis [6-9].
In this study, we investigated the expression of
CyclinD1 in 5 different pathological types of endometrial
diseases, including simple hyperplasia, atypical complex
hyperplasia, endometrioid carcinoma, endometrial ser-
ous carcinoma and clear cell carcinoma, by immunohis-
tochemistry. We also followed-up the patients and
executed survival analysis to explore the possibility of




Different types of endometrial samples were obtained
from the Department of Pathology, Qilu HospitalFigure 2 The comparison of the expressions of CyclinD1 in different paffiliated to Shandong University after getting approval
from an Institutional Review Board. Informed consent
was obtained from all the patients. All samples were
routinely fixed with 10% formaldehyde and embedded
with paraffin. Histologic features of all cases were stud-
ied with hematoxylin-eosin staining (HE) and diagnosed
by two clinical pathologists following established histo-
pathologic criteria of the International Federation of
Gynecology Oncology (FIGO) [10,11]. The samples in-
clude simple hyperplasia (n = 27), atypical complex
hyperplasia (n = 41), endometrioid carcinoma (n = 103),
serous carcinoma (n = 21) and clear cell carcinoma (n =
9). The vast majority of the carcinomas were histologically
pure; where mixed, the second component constituted less
than 10% of the total tumor volume.
Immunohistochemical analysis
The streptavidin-peroxidase-biotin (SP) immunohisto-
chemical method was performed on the paraffin sections
to study the expression of CyclinD1. Briefly, 4-μm-thick
paraffin-embedded tissue sections were deparaffinized
with xylene and hydrated through gradient alcohols.
Antigen retrieval was achieved by autoclave (170 KPa) in
EDTA buffer. Followed that, the slides were treated
with a blocking protein (Zhongshan Biotechnology
Company, Beijing, China). The sections were incubated
with mouse anti-human monoclonal CyclinD1 antibody
(1:1000; Zhongshan Biotechnology Company, Beijing,
China) overnight at 4°C. An avidin-biotin-peroxidase
complex (Dako, Denmark) with DAB as chromogen was
used for detecting antibody binding. Secondary antibody
was biotinylated anti-rabbit IgG and anti-mouse IgG/
IgM (Dako, Denmark) primary antibodies. Representa-
tive sections of breast carcinoma served as positiveathological types of endometrial diseases.
Table 2 Statistical comparisons of five endometrial lesions
Parameter a vs. Parameter b Positives (Parameter a) Positives (Parameter b) χ2value* p value*
Simple hyperplasia vs. atypical complex hyperplasia 8/27(30%) 20/41(49%) 2.465 0.116
Simple hyperplasia vs. endometrioid carcinoma 8/27(30%) 54/103(52%) 4.457 0.035
Simple hyperplasia vs. endometrial serous carcinoma 8/27(30%) 8/21(38%) 0.381 0.537
Simple hyperplasia vs. clear cell carcinoma 8/27(30%) 6/9(67%) 3.50*** 0.111**
Atypical complex hyperplasia vs. endometrioid carcinoma 20/41(49%) 54/103(52%) 0.156 0.693
Atypical complex hyperplasia vs. endometrial serous carcinoma 20/41(49%) 8/21(38%) 0.640 0.424
Atypical complex hyperplasia vs. clear cell carcinoma 20/41(49%) 6/9(67%) 4.32*** 0.467**
Endometrioid carcinoma vs. endometrial serous carcinoma 54/103(52%) 8/21(38%) 1.433 0.231
Endometrioid carcinoma vs. clear cell carcinoma 54/103(52%) 6/9(67%) 4.18*** 0.500**
Endometrial serous carcinoma vs. clear cell carcinoma 8/21(38%) 6/9(67%) 4.20*** 0.236
*: We took partitioning Chi-squares when individual comparisons were performed, in order to avoid amplifying the probability to commit type I mistake, p value
should be reset as p’ = 1-m√(1-p), “m” represented group numbers. In this case, p’ = 1-5√(1-0.05) = 0.005, so we considered p < 0.005 as statistically significant.
**: When expected cell value was 5 or less, we used Fisher’s exact test.
***: The expected cell values were 3.50, 4.32, 4.18 and 4.20 for simple hyperplasia vs. clear cell carcinoma, atypical complex hyperplasia vs. clear cell carcinoma,
endometrioid carcinoma vs. clear cell carcinoma and endometrial serous carcinoma vs. clear cell carcinoma, respectively.
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CyclinD1 with non-immune IgG as negative controls.
Evaluation of immunohistochemical staining
Cyclin D1 staining was evaluated in the glandular epi-














≤40 51 27 24 0.53 2.362 0.307
41-59 103 51 52 0.50
≥60 47 18 29 0.38
Pathological type
Simple hyperplasia 27 8 19 0.30 6.549 0.162
Atypical complex
hyperplasia
41 20 21 0.49
Endometrioid
carcinoma
103 54 49 0.52
Endometrial serous
carcinoma
21 8 13 0.38
Clear cell carcinoma 9 6 3 0.67
Invasion
None 5 3 2 0.60 1.258 0.533
<1/2 90 43 47 0.48
≥1/2 38 22 16 0.58
Metastasis
No 106 50 56 0.47 4.468 0.035
Yes 27 18 9 0.67atypical complex hyperplasia, and adenocarcinoma. Two
parameters were taken into consideration: the intensity
of nuclear staining and the extent (percentage of positive
cells). Fields for calculating percentage of immune-
reactive nuclei were selected based on best tissue preser-
vation and, where there was less artifact, wrinkling or
folding. Since the immune-reactivity may not be uniform
among nuclei on any given case, we determined grade as
the most frequently observed pattern. The intensity of
nuclear staining was graded as no staining (0), weak
(1+), moderate (2+), or strong (3+). The extent was
semi-quantitatively estimated with a range of 0% to
100%. Percentage was estimated by counting at least 50
nuclei and then establishing the ratio of immune-
reactive nuclei to total number of nuclei multiplied by
100; percentages were rounded to the nearest 10%.
When less than 10% of cells were positive, a score of 0
was used, 10% to 30% cell positivity was scored as 1,
31% to 60% positivity was scored as 2, and more than
60% positive cells was labeled as 3. However, the statis-
tical analysis was based on the data distribution using a
continuous range from 1% to 100% reactive cells.Survival analysis
Medical records of these 201 patients from Medical
Records Center of Qilu Hospital were checked after
getting the approval from Institutional Review Board.
Follow-up survey was implemented by telephone calls
and clinics to record the survival time of these 201 pa-
tients. We adopted Type I censoring, stopping the
survey at the predetermined time September, 1st, 2012,
at which point any subjects remaining are right-
censored. Patients’ death from endometrial diseases were
considered as the endpoint event.
Figure 3 Kaplan-Meier survival curve of the expression CyclinD1 in 201 patients with endometrial diseases. Kaplan-Meier analysis of
patients with and without CyclinD1 expression. The blue line represents the patients with CyclinD1 negative expression; the green line represents
the patients with CyclinD1 positive expression. It clearly showed the patients with negative expression of CyclinD1 had higher overall survival
rates than those with positive expression of CyclinD1.
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Comparison of CyclinD1 expression in different status of
the endometrium was assessed by Partitioning Chi-squares
and Fisher’s exact test when an expected cell value was 5 or
less by PASW Statistics 18.0 software. Survival curves were
created from Kaplan-Meier method with the log-rank test.
Comparisons were made by Cox’s proportional hazards
model regression. Results were presented in the form of
hazard ratios (HR) and 95% confidence interval (95CI). A p
< 0.05 was considered statistically significant.Results
Expression of CyclinD1 in endometrial diseases
The CyclinD1 protein staining was captured specifically
in endometrial glandular epithelial cell nuclei, with
strong intensity of concentrated staining in endometrioid
carcinoma and ESC. Nevertheless, the staining was typically
of moderate in ACH and clear cell carcinoma, or weak in-
tensity in simple hyperplasia. Representative images
depicting CyclinD1 staining patterns in different lesions
are illustrated in Figure 1 (A-D). The positive staining was
observed in 8 of the 27 patients (30.0%) with simple
hyperplasia, 49% (20/41) in atypical complex hyperplasia,
52% (54/103) in endometrioid carcinoma, 38% (8/21) in
endometrial serous carcinoma and 67% (6/9) in clear cell
carcinoma. A detailed summary of the data is summarized
in Table 1 and illustrated in Figure 2.Statistical comparisons of CyclinD1 expression in
endometrial lesions
Partitioning Chi-squares was applied to compare CyclinD1
expression in these five endometrial lesions individually. In
order to avoid amplifying the probability to commit type I
mistake, p value was reset as p’ = 1-m√ ((1)-p), ”m“ repre-
sented group numbers. In this case, p’ = 1-5√ ((1)-0.05) =
0.005, so we considered p < 0.005 as statistically significant.
Although atypical complex hyperplasia, endometrioid car-
cinoma and clear cell carcinoma showed more positive
staining compared with simple hyperplasia and endometrial
serous carcinoma, the p value was larger than 0.005 after
comparing CyclinD1 expression in five endometrial lesions
with each other respectively. The expression showed no
statistical significance in different endometrial lesions (p >
0.005). The corresponding statistical comparison results are
listed in Table 2.
Correlation of CyclinD1 expression with the clinic-
pathological features of the endometrial lesions
The clinic-pathological variables included the age, patho-
logical type, metastasis and invasion. The ratio of positive
expression of CyclinD1 was 53.0%, 50.0% and 38.0% in ≤40,
41-59, ≥60 age group respectively (p > 0.05). The positive
rate of the CyclinD1 expression was 30.0%, 49.0%, 52%,
38% and 67% in simple hyperplasia, ACH, endometrioid
carcinoma, ESC and CCC each (p > 0.05). The ratio of posi-
tive expression of CyclinD1 was 47.0% in the non-
Table 4 Multivariate cox regression analysis of CyclinD1
expression and clinicopathological variables
Category Hazard ratio P-value 95.0%CI for
HR
Lower Upper




Pathogenic types 1.474 0.651 0.274 7.919
I
II










Metastasis 10.198 0.000 3.691 28.176
Yes
No
CyclinD1 2.765 0.017 1.201 6.363
+
-
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indicated that CyclinD1 overexpression was related with
tumor metastasis. The CyclinD1 expression rate was 60%
in non-invasion group, 48% in <1/2 invasion group and
58% in ≥1/2 invasion group individually (p > 0.05), which
meant that CyclinD1 overexpression had no relationship
with tumor invasion. In conclusion, the expression of
CyclinD1 was not correlated with age, pathological types
and invasion (p > 0.05). However, its expression was
correlated with metastasis (p < 0.05). The corresponding
statistical results are listed in Table 3.
Survival analysis
Kaplan-Meier survival curve of the expression CyclinD1 in
201 patients with endometrial diseases
Between 2007 and 2011, these 201 patients were con-
secutively diagnosed and treated in our hospital; me-
dian and mean ages were 52.6 and 53 years. Median
follow-up period for 201 cases was 39.4 months ran-
ging from 4 months to 68 months. The average median
survival time was 42 months. The prognosis of patientswere significantly determined between the two groups
regarding CyclinD1 staining [log-rank(Mantel-Cox),
χ2 =12.293,p = 0.000 ( P<0. 05)]. The survival curve for
CyclinD1 staining group zigzagged obviously lower
than CyclinD1 empty group, which is illustrated in
Figure 3.
Multivariate Cox regression analysis of CyclinD1 expression
and clinic-pathological features
Multivariate Cox regression analysis demonstrated that
of the factors being studies, only metastasis (HR10.198,
95% CI: 3.691–28.176, p < 0.05) and CyclinD1 staining
(HR2.765, 95% CI: 1.201–6.363, p < 0.05) were signifi-
cantly associated with prognosis. However, the age,
pathogenic types, pathological types and invasion were
not tightly associated with prognosis. The detailed in-
formation was summarized in Table 4.
Discussion
Tumor is a type of general, systematic and step-by-step
developing disease involving a series of factors; it is
caused by the mutation of the oncogenes and disorders
of some genes [12]. Endometrial carcinoma is a malig-
nant cancer that derives from endometrial glandular
epithelium. The formation of organs and tissues of
female reproductive tract is through the development,
evolvement and differentiation of Miller’s tube. The
epithelium of Miller’s tube is characterized by a
multiple differentiation potential. After birth, these un-
differentiated embryonic cells retained within the ger-
minal layer of tissue in the mature organism. So when
cancers happen in the female reproductive tract organs
or tissues, not only can they form the same type of
cancer tissues with the original tissues, namely
endometrial adenocarcinoma, [13] but also they can
develop other types of cancers which derive from
the multidifferentiation of Miller tubular epithelium.
These types of cancers are such as endometrial serous
carcinoma, clear cell carcinoma, mucinous adenocar-
cinoma, squamous cell carcinoma, mixed carcinoma
and undifferentiated carcinoma and etc. [14,15] This
situation leads to the complexity and diversity of endo-
metrial diseases.
CCND1, as a proto-oncogene located on chromo-
some 11q13, has been studied in recent years.
CyclinD1, the protein encoded by the gene, is origin-
ally proposed by Motokura et al, they found CyclinD1’s
over expression in the parathyroid glands [16].
CyclinD1 protein plays an important and positive role
during the key rate-limiting point G1→ S phase transi-
tion in the cell cycle. It can activate CDK4 or CDK6 to
phosphosphorylate a series of key substrates, such
as protein Rb, in that case, the transcription factors
will be released to promote synthesis of DNA and
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sential sensor and activator of cell cycle initiation and
progression; Cyclin D1 amplification and gain copies
with consequent protein over-expression have been
frequently described in multiple myeloma, T cutaneous
lymphomas and in solid cancer [18], such as oral squa-
mous cell carcinoma, lung cancer, melanoma, breast
cancer [19,20]. A recent study has shown that strong
nuclear EGFR expression in colorectal carcinomas is
associated with cyclin-D1 but not with gene EGFR
amplification [21].
The results of this research showed the expression of
CyclinD1 increased in the order of simple hyperplasia,
ACH, endometrioid carcinoma, CCC except ESC, the
statistical comparisons of these types with each other
demonstrated no statistical significance (P > 0.005).
However, the further analysis showed that patients
with CyclinD1 expression usually accompanied by
lymph node metastasis and poor prognosis (P <0. 05),
this is consistent with Nikaido’s report. [21]. Thus,
CyclinD1’s over expression is positively correlated with
the lymph node metastasis and poor prognosis. As a
positive regulator of cell cycle, CyclinD1’s over expres-
sion may lead to uncontrolled cell proliferation. Even
though its expression rate increased with the level of
malignancy of the endometrial lesions, it still lacks the
specificity to differentiate non-neoplastic and neoplas-
tic endometrial tissues. Therefore, we could not merely
use CyclinD1 as a diagnostic marker when we confront
a dilemma of distinguishing non-neoplastic and neo-
plastic lesions, but its application could predict the
prognosis more credibly and accurately. In other
words, CyclinD1 could be an applicable indicator for
the prognosis of endometrial cancer. Future studies on
the role of CyclinD1 of endometrial carcinogenesis are
needed.Conclusion
In conclusion, our study demonstrated that the expres-
sion of CyclinD1 was up-regulated with the level of ma-
lignancy of the endometrial lesions; it lacks the
specificity to differentiate non-neoplastic and neoplastic
endometrial tissues. The results showed that the
expression of CyclinD1 was tightly correlated with the
metastasis of endometrial cancers. The facts above dem-
onstrated that CyclinD1 play an important role in the
formation and development of endometrial cancers. Sig-
nificantly, Kaplan-Meier survival analysis and multivari-
ate Cox regression analysis showed that CyclinD1and
lymph node metastases were risk markers of overall sur-
vival; they affected the patients’ prognosis. Therefore,
the evaluation of CyclinD1 may assist in predicting the
prognosis of endometrial carcinoma as a supplement toER, PR and P53. Such knowledge may help to identify
new strategies for endometrial cancer treatment.
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